RXSTRXSTHealthcare · Medical Devices

RXST Stock Forecast: RxSight, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.46
−3.25% on the day

The 10 Wall Street analysts covering RxSight, Inc. hold a median 12-month price target of $6 — +34.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 54 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$193.3M
Ticker Nerd rank
54/ 100
Median analyst target
$6.00
Analysts covering
10
Revenue$33.7M+0.3% y/y
Operating income−$13.8M
Net income−$12.1M
Free cash flow−$11.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.2%
1M
−8.6%
YTD
−57.2%
1Y
−50.2%
From 52W high
−65.9%
From 52W low
0.0%
$4
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores RxSight, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
54/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Quality
77
Revisions
73
Issuance
53
Volatility
51
Momentum
25
Growth
22
Value
12

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RXST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RXST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26RXSTHigh $8.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
1
Buy
7
Hold
2
Sell
$5.00
Low
$6.00
Median
$8.00
High

The green dot is the last close — the median target sits +34.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
4 Nov 2026NeedhamMaintainsBuy$11 → $7.00
4 Nov 2026Piper SandlerMaintainsNeutral$10 → $8.00
4 Nov 2026Wells FargoMaintainsEqual-Weight$9.00 → $6.00
22 Sept 2026B of A SecuritiesMaintainsUnderperform$6.50 → $5.50
22 Sept 2026JefferiesMaintainsHold$6.50 → $5.75
10 Aug 2026StifelMaintainsHold$8.00 → $7.00
6 Aug 2026UBSMaintainsNeutral$5.50 → $6.30
28 July 2026UBSAssumesNeutral$9.00 → $5.50
7 July 2026B of A SecuritiesMaintainsUnderperform$8.00 → $6.50
7 July 2026NeedhamReiteratesBuy$11
7 May 2026NeedhamMaintainsBuy—
7 May 2026Wells FargoMaintainsEqual-Weight—
9 Mar 2026StifelMaintainsHold—
26 Feb 2026NeedhamReiteratesBuy—
26 Feb 2026Piper SandlerMaintainsNeutral—
26 Feb 2026UBSMaintainsNeutral—
20 Jan 2026Piper SandlerMaintainsNeutral—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
6 Nov 2025JP MorganMaintainsUnderweight—
6 Nov 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RXST.

Market Radar

This page is one stock. Monday covers all of them.

RXST appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RXST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, RxSight, Inc. returned −50.2% against +6.9% for the S&P 500, dividends included.

RXST vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26RXSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RXST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.6×

Cheaper than 55% of US stocks

Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
76.7%

Higher than 88% of US stocks

Operating margin
−50.4%

Higher than 18% of US stocks

Net margin
—
Returns & dividend
Return on equity
−20.1%

Higher than 32% of US stocks

Return on assets
−11.8%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • RxSight, Inc. has a market value of $193.3M.

  • Revenue in the twelve months to 30 June 2026: $127.6M. The latest quarter grew 0.3% year on year.

  • Net income over the same four quarters: −$46.9M, a −36.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.13.

  • Free cash flow in the twelve months to 30 June 2026: −$27.2M.

  • Shares outstanding: 41.6M.

  • RxSight, Inc. employs 461 people — $277K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

RXST and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
RXSTRxSight, Inc.$193.3M54
ELMDElectromed, Inc.$191.7M89
QSIQuantum-Si, Inc.$199.7M49
CLPTClearPoint Neuro, Inc.$221.5M29
MXCTMaxCyte, Inc.$146.8M94
INGNInogen, Inc.$144.3M77
OFIXOrthofix Medical, Inc.$240.4M60

Take a look at RXST’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own RxSight, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RXST

What is the RXST stock price forecast for 2026-2027?

The 10 Wall Street analysts covering RxSight, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RXST stock a buy right now?

Of the 10 analysts covering RxSight, Inc., 1 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks RxSight, Inc. 54 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RXST?

As at 21 Nov 2026, RxSight, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will RXST stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +34.5% from the last close, and Ticker Nerd's factor model ranks RxSight, Inc. 54 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RXST stock forecast for 2030?

No analyst covering RxSight, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has RXST stock performed over the past year?

RxSight, Inc. returned -50.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does RxSight, Inc. do?

RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery. The company’s core offering is the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens and the Light Delivery Device, along with related accessories used by eye care professionals.

Company

About RxSight, Inc.

RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery. The company’s core offering is the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens and the Light Delivery Device, along with related accessories used by eye care professionals. This platform allows doctors to customize and optimize a patient’s visual acuity after implantation, addressing a major need in premium cataract care. RxSight serves ophthalmic surgeons, ambulatory surgery centers, and ophthalmology practices, with its products used in the U.S. cataract surgery market and selected international markets through distribution partners. Headquartered in Aliso Viejo, California, RxSight operates as a specialized medical device business centered on adjustable intraocular lens technology and post-surgical vision refinement.

CEO Mr. Aziz Mottiwala M.B.A. · 461 employees · United States · https://rxsight.com